CTNM vs RTX · $429.6M cap vs P/E 36, rev $46.78B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Christopher T. Calio J.D..
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
CTNM currently screens at market cap $429.6M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the CTNM and RTX stock pages for the full models.
Not investment advice.